Svetlana Golocorbin-Kon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3760404/publications.pdf

Version: 2024-02-01

63 1,304 papers citations h-i

331670 377865
21 34
h-index g-index

63 63 docs citations

63 times ranked 1181 citing authors

#	Article	IF	CITATIONS
1	Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. Frontiers in Pharmacology, 2018, 9, 1283.	3.5	159
2	Application of bile acids in drug formulation and delivery. Frontiers in Life Science: Frontiers of Interdisciplinary Research in the Life Sciences, 2013, 7, 112-122.	1.1	100
3	Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. Frontiers in Pharmacology, 2018, 9, 1382.	3.5	78
4	Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. Journal of Pharmaceutical Innovation, 2014, 9, 150-157.	2.4	58
5	An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharmaceutical Development and Technology, 2015, 20, 702-709.	2.4	56
6	Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1290-1297.	2.8	49
7	The influence of $3\hat{l}\pm$, $7\hat{l}\pm$ -dihydroxy-12-keto- $5\hat{l}^2$ -cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 137-142.	1.6	42
8	Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 99-108.	1.6	41
9	Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scientific Reports, 2020, 10, 106.	3.3	41
10	Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. Journal of Microencapsulation, 2015, 32, 151-156.	2.8	38
11	Experimental and chemometric study of antioxidant capacity of basil (Ocimum basilicum) extracts. Industrial Crops and Products, 2017, 100, 176-182.	5.2	37
12	Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Design, Development and Therapy, 2014, 8, 1221.	4.3	32
13	Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Design, Development and Therapy, 2014, 8, 1003.	4.3	30
14	Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies. Scientific Reports, 2020, 10, 7715.	3.3	30
15	Coping with the burden of the COVID-19 pandemic: a cross-sectional study of community pharmacists from Serbia. BMC Health Services Research, 2021, 21, 304.	2.2	29
16	Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. European Journal of Drug Metabolism and Pharmacokinetics, 2009, 34, 93-99.	1.6	28
17	Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 748-754.	2.8	28
18	Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. Pharmacological Research, 2019, 146, 104333.	7.1	27

#	Article	IF	Citations
19	Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 269-280.	1.6	23
20	Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 741-747.	2.8	22
21	Reasons for and frequency of off - label drug use. Medicinski Pregled, 2015, 68, 35-40.	0.1	22
22	Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid. Therapeutic Delivery, 2018, 9, 811-821.	2.2	21
23	Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment. Therapeutic Delivery, 2019, 10, 99-106.	2.2	19
24	Environmental Transformation of Pharmaceutical Formulations: A Scientific Review. Archives of Environmental Contamination and Toxicology, 2019, 77, 155-161.	4.1	18
25	Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects. European Journal of Pharmaceutical Sciences, 2017, 106, 1-9.	4.0	17
26	A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi Pharmaceutical Journal, 2020, 28, 165-171.	2.7	17
27	Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation. Pharmacological Reports, 2020, 72, 368-378.	3.3	16
28	An Insight on Differences in Availability and Reimbursement of Orphan Medicines Among Serbia, Bulgaria and Sweden. Biotechnology and Biotechnological Equipment, 2012, 26, 3236-3241.	1.3	15
29	Modulatory Nano/Micro Effects of Diabetes Development on Pharmacology of Primary and Secondary Bile Acids Concentrations. Current Diabetes Reviews, 2020, 16, 900-909.	1.3	14
30	DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 1-14.	1.6	13
31	Internet Marketing of Cardioprotective Dietary Supplements. Journal of Alternative and Complementary Medicine, 2020, 26, 204-211.	2.1	13
32	«p»Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, inÂPancreatic β-Cells. Nanotechnology, Science and Applications, 2020, Volume 13, 1-9.	4.6	13
33	An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques. PLoS ONE, 2019, 14, e0214984.	2.5	12
34	Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Therapeutic Delivery, 2019, 10, 563-571.	2.2	12
35	Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids. Therapeutic Delivery, 2019, 10, 573-583.	2.2	12
36	The influence of probiotics on the cervical malignancy diagnostics quality. Vojnosanitetski Pregled, 2011, 68, 956-960.	0.2	11

#	Article	IF	Citations
37	Bile acid-polymer-probucol microparticles: protective effect on pancreatic \hat{l}^2 -cells and decrease in type 1 diabetes development in a murine model. Pharmaceutical Development and Technology, 2019, 24, 1272-1277.	2.4	11
38	The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 881-890.	1.6	9
39	Histological effects of pharmacologically active human bile acid nano/micro-particles in Type-1 diabetes. Therapeutic Delivery, 2020, 11, 157-171.	2.2	9
40	Pharmacological effects of secondary bile acid microparticles in diabetic murine model. Current Diabetes Reviews, 2020, 16, .	1.3	9
41	Interaction Between Different Extracts of Hypericum perforatum L. from Serbia and Pentobarbital, Diazepam and Paracetamol. Molecules, 2014, 19, 3869-3882.	3.8	8
42	High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 1005-1011.	1.6	8
43	Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes. Journal of Diabetes, 2016, 8, 238-245.	1.8	7
44	In silico Discovery of Resveratrol Analogues as Potential Agents in Treatment of Metabolic Disorders. Current Pharmaceutical Design, 2019, 25, 3776-3783.	1.9	7
45	Comparison of Dissolution Profiles and Serum Concentrations of Two Lamotrigine Tablet Formulations. Drugs in R and D, 2011, 11, 53-60.	2.2	5
46	Pharmacokinetic and drug absorption profiles of the anti-hyperglycaemic agent gliclazide in oral tissue-targeted microcapsules in rats. Scripta Medica, 2020, 51, 15-20.	0.1	5
47	The Effect of Diabetes and Hypertension on the Placental Permeation of the Hydrophilic Drug, Ranitidine. Placenta, 2016, 48, 144-150.	1.5	4
48	The effect of magnesium stearate and sodium starch glycolate on powder flowability. Acta Periodica Technologica, 2019, , 304-310.	0.2	4
49	Influence of Bile Acids in Hydrogel Pharmaceutical Formulations on Dissolution Rate and Permeation of Clindamycin Hydrochloride. Gels, 2022, 8, 35.	4.5	4
50	Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: A Pharmacoinformatic Preliminary Study. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 1407-1413.	1.7	3
51	The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection. Vojnosanitetski Pregled, 2021, 78, 708-715.	0.2	3
52	Hypoglycemic effect of herbicide 2,4-dichlorophenoxyacetic acid (2,4-D). Pesticidi I Fitomedicina = Pesticides and Phytomedicine, 2010, 25, 349-352.	0.2	3
53	The significance of dosage forms for pharmacovigilance in the case of topical corticosteroids. Hospital Pharmacology, 2019, 6, 800-806.	0.3	3
54	Dried blood spot: Utilizing dry blood for pharmacokinetic investigations - an old method with great future for therapeutic drug monitoring. Vojnosanitetski Pregled, 2018, 75, 1222-1225.	0.2	2

#	Article	IF	CITATIONS
55	Drug sodium intake: Warning in cardiovascular diseases treatment. Hospital Pharmacology, 2020, 7, 913-922.	0.3	2
56	Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. Scientific Reports, 2021, 11, 22123.	3.3	2
57	New horizons of methotrexate application. PONS - Medicinski Casopis, 2020, 17, 20-26.	0.0	1
58	Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights. European Journal of Drug Metabolism and Pharmacokinetics, 2021, , 1.	1.6	1
59	Effects of occupational exposure to pesticides and consumption of alcoholic beverages on liver functions. Zdravstvena Zastita, 2013, 42, 47-55.	0.2	1
60	Consumption and pharmaceutical-technological formulations of herbal medicines in Serbia. Timocki Medicinski Glasnik, 2019, 44, 56-62.	0.0	0
61	Botulinum toxin: Poison and medicine. PONS - Medicinski Casopis, 2019, 16, 24-31.	0.0	0
62	The role of pharmacists in crisis management and humanitarian missions: Current state and perspectives. PONS - Medicinski Casopis, 2021, 18, 41-52.	0.0	0
63	What Is fishy in asymptomatic patients?: Co-occurrence of Aerococcus urinae infection in pediatric patient with phimosis. Acta Facultatis Medicae Naissensis, 2021, 38, 399-402.	0.4	O